News

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

In addition, authors of a research letter noted that patients with vitiligo demonstrated a comparable risk of myocardial infarction and cerebrovascular accident.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

Marc Hurlbert, PhD, discusses how the Melanoma Research Alliance works with dermatology clinicians to provide fundings and resources for melanoma research.

Researchers found that the diameter of cutaneous melanoma demonstrated a weak positive correlation with tumor thickness.

Dozens of investigators shared findings to advance care in patients with melanoma during Mohs micrographic surgery.

The Harris brothers serve 2 predominantly elderly populations and appreciate the opportunity to provide solutions for the growing complexity of skin cancer issues as patients live longer.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month and Melanoma Monday.

Keep up with the latest headlines in dermatology from the past week, including the invention of a groundbreaking method for detecting skin cancer using Terahertz waves, a survey indicative of young people's perceptions of sun exposure, and more.

In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more.

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.

Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.

Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.

Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.

May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

The new research will compare eblasakimab to dupilumab and lebrikizumab.

This recap of skin cancer innovations accompanies the cover story of our May publication.

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.

While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.

These challenges may exacerbate racial inequities in care access and quality, according to a new study.

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.

Review Dermatology Times' coverage of Rosacea Awareness Month.

Dermatology Times is looking back on the top stories in dermatology from the month of April.

A decision from the FDA is expected in the second half of 2024.